MENU
ALLO
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Allogene Therapeutics (ALLO) Earnings Date & Reports

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases... Show more

Industry: #Biotechnology
A.I. Advisor
published Earnings

ALLO is expected to report earnings to rise 2.57% to -28 cents per share on April 30

Allogene Therapeutics ALLO Stock Earnings Reports
Q1'25
Est.
$-0.29
Q4'24
Beat
by $0.04
Q3'24
Beat
by $0.01
Q2'24
Est.
$-0.35
Q1'24
Beat
by $0.03
The last earnings report on March 13 showed earnings per share of -28 cents, beating the estimate of -31 cents. With 1.97M shares outstanding, the current market capitalization sits at 297.65M.
View a ticker or compare two or three
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of allogeneic chimeric antigen receptor therapy

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
210 East Grand Avenue
Phone
+1 650 457-2700
Employees
233
Web
https://www.allogene.com